Aside from demonstrating clear improvements in cognitive function on testing in those with minimal HE, and prevention of HE in the treatment group, Patel et al. demonstrated reduced TNFα, IL-10 and TLR-4 levels in the group of rifaximin-treated cirrhotic patients compared with placebo. The gene discussed is TLR4; the disease is hereditary elliptocytosis.